Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Granger

Showing results (501-510 of 1,253) with videos related to

Pageof 126
Sort By:
American Heart Journal|December 9, 2019
High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarctionJay S Shavadia, Christopher B Granger, Wendimagegn Alemayehu, et al.
American Heart Journal|November 2, 2013
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction studyAkshay Bagai, Paul W Armstrong, Amanda Stebbins, et al.
Heart (British Cardiac Society)|March 19, 2005
Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trialR C Welsh, W Chang, P Goldstein, et al.
Circulation|December 8, 2004
Lessons learned from a clinical trialPaul W Armstrong, L Kristin Newby, Christopher B Granger, et al.
Circulation|January 5, 2000
Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial InvestigatorsB S Crenshaw, C B Granger, Y Birnbaum, et al.
American Heart Journal|May 22, 2012
Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trialRajendra H Mehta, Padma Kaul, Renato D Lopes, et al.
JAMA|January 4, 2007
Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial, Paul W Armstrong, Christopher B Granger, et al.
Circulation|April 1, 2020
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUSJohn H Alexander, Daniel Wojdyla, Amit N Vora, et al.
European Heart Journal|January 13, 2006
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarctionWei-Ching Chang, Padma Kaul, Yuling Fu, et al.
American Heart Journal|March 5, 2013
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary interventionCynthia M Westerhout, Karen S Pieper, Stefan K James, et al.
Pageof 126

Showing results (501-510 of 1,253) with videos related to

Sort By:
Pageof 126
American Heart Journal|December 9, 2019
High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarctionJay S Shavadia, Christopher B Granger, Wendimagegn Alemayehu, et al.
American Heart Journal|November 2, 2013
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction studyAkshay Bagai, Paul W Armstrong, Amanda Stebbins, et al.
Heart (British Cardiac Society)|March 19, 2005
Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trialR C Welsh, W Chang, P Goldstein, et al.
Circulation|December 8, 2004
Lessons learned from a clinical trialPaul W Armstrong, L Kristin Newby, Christopher B Granger, et al.
Circulation|January 5, 2000
Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial InvestigatorsB S Crenshaw, C B Granger, Y Birnbaum, et al.
American Heart Journal|May 22, 2012
Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trialRajendra H Mehta, Padma Kaul, Renato D Lopes, et al.
JAMA|January 4, 2007
Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial, Paul W Armstrong, Christopher B Granger, et al.
Circulation|April 1, 2020
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUSJohn H Alexander, Daniel Wojdyla, Amit N Vora, et al.
European Heart Journal|January 13, 2006
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarctionWei-Ching Chang, Padma Kaul, Yuling Fu, et al.
American Heart Journal|March 5, 2013
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary interventionCynthia M Westerhout, Karen S Pieper, Stefan K James, et al.
Pageof 126